Drug Trial Radar · NCT07339176
Intratumoral N17350 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
275
Planned (sponsor's estimate)
Start
May 25, 2026
Primary completion
Jul 2028
Study completion Nov 2029
Sponsor
- Lead sponsor
- Onchilles Pharma IncIndustry
- Sponsor type
- Industry
- Collaborators
- Onchilles Pharma Pty Ltd
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection). This is an open-label study, meaning all participants will receive N17350 and there is no placebo. Participants will: 1. Receive injections of N17350 into tumor lesions every second week for 8 or 12 weeks 2. Visit the clinic regularly for checkups, blood tests, and monitoring for side effects 3. Have imaging scans (such as CT or MRI) to measure tumors and assess response 4. Provide blood samples and, when required, tumor samples to help researchers understand how N17350 affects the tumor and the immune system
Conditions
- Neoplasms, Solid Tumor
- Breast Neoplasms, Triple-Negative
- Squamous Cell Carcinoma of Skin
- Melanoma
- Head and Neck Neoplasms
- Carcinoma, Squamous Cell
- Carcinoma, Non-Small-Cell Lung
Interventions
N17350Biological
N17350 is a recombinant mutant porcine pancreatic elastase (PPE) developed to target the neutrophil elastase (ELANE) pathway.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Safety and tolerability of intratumoral N17350, including incidence of DLTs and adverse eventsTime frame: DLTs: First 28 days; TEAEs/SAEs/laboratory abnormalities: From enrollment through 30 days after last dose assessed up to 4 months
- Phase 2: Objective Response Rate (ORR) of lesions at RP2D/optimal dose(s)Time frame: From baseline disease assessment until disease progression or initiation of a new anticancer therapy, assessed up to 15 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California · Not yet recruiting
UCLA - Jonsson Comprehensive Cancer Center
Los Angeles, California · Recruiting
Scripps Clinic Torrey Pines - La Jolla
San Diego, California · Recruiting
University of California, San Francisco
San Francisco, California · Not yet recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Calvary Mater Hospital
Newcastle, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre (PMCC)
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.